
    
      This study is divided into 2 phases conducted in sequence for a total of 6 visits: Phase I
      (Screening/Eligibility) which includes a Screening Visit, followed by 2 Eligibility Visits
      (E1 and E2) and Phase II (Treatment/Follow-up) which includes 3 visits at Week 2, Week 6, and
      Month 3. Following washout of any IOP-lowering medication, subjects who meet all
      inclusion/exclusion criteria at both Eligibility visits and had IOP measurements within the
      specified range during this period will be randomized to Phase II.
    
  